Literature DB >> 7296205

Tolerance of brain to multiple courses of radiation therapy. I. Clinical experiences.

A Dritschilo, J E Bruckman, J R Cassady, J A Belli.   

Abstract

Patients with recurrent brain tumours years after initial radiation therapy pose a difficult management decision. Should retreatment be performed with irradiation, which carries a risk of necrosis, or should retreatment be with less effective agents but without unnecessary risks? We present the results of retreatment of 32 patients at the Mayo Clinic and the Joint Center for Radiation Therapy. Clinical improvement was seen in all retreated patients. The median survival was 36 months after completion of the second course of irradiation. Eight patients (25%) were alive, free of disease, from 22 to 315 months after retreatment. Of the 11 patients alive at the time of analysis, eight were experiencing productive lives and three were suffering from severe neurological damage. Evidence of brain necrosis was observed in two patients (6%); however, only 10/21 patients underwent autopsy examinations. Reirradiation of patients with late recurrences of brain tumours may offer neurological improvement and prolonged survival without excessive risk of necrosis.

Entities:  

Mesh:

Year:  1981        PMID: 7296205     DOI: 10.1259/0007-1285-54-645-782

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  13 in total

1.  Reirradiation for recurrent cerebral astrocytoma.

Authors:  D L Silbergeld; B R Griffin; G A Ojemann
Journal:  J Neurooncol       Date:  1992-02       Impact factor: 4.130

2.  Cyberknife stereotactic radiosurgery for the re-irradiation of brain lesions: a single-centre experience.

Authors:  Daniela Greto; Lorenzo Livi; Pierluigi Bonomo; Laura Masi; Beatrice Detti; Icro Meattini; Monica Mangoni; Raffaella Doro; Virginia Favuzza; Samantha Cipressi; Carmine Iermano; Ivano Bonucci; Mauro Loi; Gianpaolo Biti
Journal:  Radiol Med       Date:  2014-01-28       Impact factor: 3.469

3.  Seizures and hemiparesis in a young woman 24 years after treatment of astrocytoma.

Authors:  J C Mazziotta; S E Jordan; M Lones; K L Black; M T Selch; G Pignatti; H V Vinters
Journal:  West J Med       Date:  1989-02

4.  Stereotactic radiosurgery for patients with recurrent intracranial ependymomas.

Authors:  Michael C Stauder; Nadia Ni Laack; Kamran A Ahmed; Michael J Link; Paula J Schomberg; Bruce E Pollock
Journal:  J Neurooncol       Date:  2012-03-23       Impact factor: 4.130

5.  Radiosurgery for recurrent brain metastases after whole-brain radiotherapy : factors affecting radiation-induced neurological dysfunction.

Authors:  Ho-Shin Gwak; Hyung Jun Yoo; Sang-Min Youn; Dong Han Lee; Mi Sook Kim; Chang Hun Rhee
Journal:  J Korean Neurosurg Soc       Date:  2009-05-31

6.  Increasing frequency of reirradiation studies in radiation oncology: systematic review of highly cited articles.

Authors:  Carsten Nieder; Nicolaus H Andratschke; Anca L Grosu
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

7.  Treatment of malignant brain tumors with focused ultrasound hyperthermia and radiation: results of a phase I trial.

Authors:  A N Guthkelch; L P Carter; J R Cassady; K H Hynynen; R P Iacono; P C Johnson; E A Obbens; R B Roemer; J F Seeger; D S Shimm
Journal:  J Neurooncol       Date:  1991-06       Impact factor: 4.130

Review 8.  The impact of technical adjuncts in the surgical management of cerebral hemispheric low-grade gliomas of childhood.

Authors:  M S Berger
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

9.  Reirradiation of recurrent medulloblastoma: does clinical benefit outweigh risk for toxicity?

Authors:  Cynthia Wetmore; Danielle Herington; Tong Lin; Arzu Onar-Thomas; Amar Gajjar; Thomas E Merchant
Journal:  Cancer       Date:  2014-07-30       Impact factor: 6.860

Review 10.  Radiotherapeutic alternatives for previously irradiated recurrent gliomas.

Authors:  Stephanie E Combs; Jürgen Debus; Daniela Schulz-Ertner
Journal:  BMC Cancer       Date:  2007-08-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.